EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia

Mana Nishida, Takeshi Horio, Yusuke Fukuda, Yuki Hayakawa, Yu Tateishi, Mayumi Akai, Masanori Emoto, Takamasa Hasegawa, Masahito Imanishi

Int. Journal of Clinical Pharmacology and Therapeutics · 2023

DOI: 10.5414/cp204408 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2023. Verfasst von Mana Nishida und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Bezafibrate, Hypertriglyceridemia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Among fibrates as triglyceride-lowering agents, bezafibrate and fenofibrate are predominantly renally excreted, while pemafibrate is mainly hepatically metabolized and biliary excreted. To elucidate possible different properties among fibrates, this retrospective observational study examined the changes in clinical laboratory parameters, including indices of renal function and glucose metabolism, in cases of switching from bezafibrate to pemafibrate. MATERIALS AND METHODS: In 93 patients with hypertriglyceridemia, the average values of laboratory parameters including serum creatinine, estimated glomerular filtration rate (eGFR), plasma glucose, and hemoglobin A1c on respective two occasions before and after switching from bezafibrate to pemafibrate were evaluated. RESULTS: Triglycerides, low-density and high-density lipoprotein cholesterol, creatine kinase, and uric acid did not change before and after switching from bezafibrate to pemafibrate. Serum creatinine significantly decreased and eGFR significantly increased after switching from bezafibrate to pemafibrate (p < 0.001, respectively). Plasma glucose tended to increase (p = 0.070) and hemoglobin A1c significantly increased (p < 0.001) after switching to pemafibrate. The degrees of changes in creatinine, eGFR, glucose, and hemoglobin A1c before and after drug switching were not affected by the presence or absence of coexisting disease, and with or without drug treatment including statin and renin-angiotensin system inhibitor. CONCLUSION: Our findings indicate that switching from bezafibrate to pemafibrate produces a significant decrease in serum creatinine and increases in eGFR and hemoglobin A1c in patients with hypertriglyceridemia, suggesting that the effects on renal function and glucose metabolism differ among fibrates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BezafibrateHypertriglyceridemiaHumansBlood GlucoseGlycated HemoglobinCreatinineTriglyceridesFibric AcidsGlucoseKidneyBenzoxazolesButyrates

Substanzen

BezafibrateBlood GlucoseGlycated HemoglobinCreatinineTriglyceridesFibric AcidsGlucose(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidBenzoxazolesButyrates

Zitieren

APA

Nishida, M., Horio, T., Fukuda, Y., Hayakawa, Y., Tateishi, Y., Akai, M., Emoto, M., Hasegawa, T., & Imanishi, M. (2023). Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204408

Vancouver

Nishida M, Horio T, Fukuda Y, Hayakawa Y, Tateishi Y, Akai M, et al. Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia. Int. Journal of Clinical Pharmacology and Therapeutics. 2023. doi:10.5414/cp204408

BibTeX
@article{Nishida2023,
  author = {Nishida, Mana and Horio, Takeshi and Fukuda, Yusuke and Hayakawa, Yuki and Tateishi, Yu and Akai, Mayumi and Emoto, Masanori and Hasegawa, Takamasa and Imanishi, Masahito},
  title = {Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2023},
  doi = {10.5414/cp204408}
}
Kostenlos starten →